Aim: To establish an efficient culture system to support embryonic stem (ES) cell differentiation into hepatocytes that coexpress F-VIII and F-IX.

Methods: Mouse E14 ES cells were cultured in differentiation medium containing sodium butyrate (SB), basic fibroblast growth factor (bFGF), and/or bone morphogenetic protein 4 (BMP4) to induce the differentiation of endoderm cells and hepatic progenitor cells. Hepatocyte growth factor, oncostatin M, and dexamethasone were then used to induce the maturation of ES cell-derived hepatocytes. The mRNA expression levels of endoderm-specific genes and hepatocyte-specific genes, including the levels of F-VIII and F-IX, were detected by RT-PCR and real-time PCR during various stages of differentiation. Protein expression was examined by immunofluorescence and Western blot. At the final stage of differentiation, flow cytometry was performed to determine the percentage of cells coexpressing F-VIII and F-IX, and ELISA was used to detect the levels of F-VIII and F-IX protein secreted into the culture medium.

Results: The expression of endoderm-specific and hepatocyte-specific markers was upregulated to highest level in response to the combination of SB, bFGF, and BMP4. Treatment with the three inducers during hepatic progenitor differentiation significantly enhanced the mRNA and protein levels of F-VIII and F-IX in ES cell-derived hepatocytes. More importantly, F-VIII and F-IX were coexpressed with high efficiency at the final stage of differentiation, and they were also secreted into the culture medium.

Conclusion: We have established a novel in vitro differentiation protocol for ES-derived hepatocytes that coexpress F-VIII and F-IX that may provide a foundation for stem cell replacement therapy for hemophilia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003324PMC
http://dx.doi.org/10.1038/aps.2010.100DOI Listing

Publication Analysis

Top Keywords

f-viii f-ix
24
hepatocytes coexpress
12
levels f-viii
12
differentiation
9
embryonic stem
8
stem cell
8
coexpress f-viii
8
growth factor
8
hepatic progenitor
8
cell-derived hepatocytes
8

Similar Publications

Impact of thyroid function on coagulation and venous thromboembolism: a two-sample mendelian randomization study.

J Thromb Thrombolysis

October 2024

Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, No.37 Guoxue Xiang, Chengdu, Sichuan province, 610041, China.

Objective: The association between thyroid function, coagulation and venous thromboembolism (VTE) has been reported in observational studies with conflicting findings. This study aimed to elucidate the causal effects of thyroid function on coagulation and VTE from a genetic perspective.

Methods: Two sample Mendelian randomization analysis was conducted using summary statistics from genome-wide association studies in a European population.

View Article and Find Full Text PDF
Article Synopsis
  • - After years of development, gene therapies for hemophilia A and B have been commercialized, effectively normalizing factor levels in some patients but demonstrating variable long-term efficacy.
  • - Clinical trials reveal issues such as liver toxicities and potential oncogenicity of AAV vectors, which complicate their long-term safety and efficacy, alongside the challenge of immune responses limiting the possibility for repeat dosing.
  • - While AAV gene therapies present new treatment options, they are not universal cures, necessitating the development of alternative gene transfer systems to address efficacy variability and improve access for ineligible patients.
View Article and Find Full Text PDF

Gene therapy - are we ready now?

Haemophilia

May 2022

Coagulation Products Safety Supply and Access Committee, World Federation of Hemophilia, Montreal, Quebec, Canada.

Introduction: Haemophilia therapy has evolved from rudimentary transfusion-based approaches to an unprecedented level of innovation with glimmers of functional cure brought by gene therapy. After decades of misfires, gene therapy has normalized factor (F)VIII and factor (F)IX levels in some individuals in the long term. Several clinical programmes testing adeno-associated viral (AAV) vector gene therapy are approaching completion with imminent regulatory approvals.

View Article and Find Full Text PDF

The supplementation of factor (F-) VIII or F-IX products for hemophilia treatment has helped in preventing arthropathy and considerably improving the quality of life (QOL) of patients. However, serious issues related to hemostatic treatment of hemophilia include the need for repeated intravenous infusion of products, inhibitor development, and hemostatic treatment for patients with inhibitors. To overcome these issues, some extended half-life products and nonclotting factor products were developed.

View Article and Find Full Text PDF

Prevalence of Coagulation Factors Deficiency among Young Adults in Saudi Arabia: A National Survey.

TH Open

October 2020

Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Alfaisal University, Riyadh, Saudi Arabia.

 Inherited bleeding disorders vary in prevalence due to genetic disparity and ethnicity. Little is known about the prevalence of coagulation factor deficiency and bleeding disorders in middle-eastern population.  Young Saudi adults with at least one positive bleeding symptom reported in semi-structured validated condensed MCMDM-1vWD questionnaire were tested for complete blood count, routine and special coagulation tests, serum ferritin level, and capillary zone electrophoresis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!